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Conclusion: RT is highly effective for refractory degenerative 
joint diseases. Prognostic factors for outcome can be 
established. Due to minimal side effects and low costs, RT 
represents an excellent treatment compared to conventional 
methods of treatment and surgery in the chronic disease. 
This study confirms by objective criteria the anti-
inflammatory efficacy of low dose RT  
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Purpose or Objective: Hospital General Universitario 
Gregorio Marañon has a long-standing tradition of IOeRT 
(Intraoperative electron Radiation Therapy), with over 1600 
procedures in its 20 year history. Since december 2013, a 
minituarized linear accelerator (LIAC) started to operate in 
our center. We describe the 22 months technical and clinical 
experience with LIAC in our consolidated IOeRT program.  
 
Material and Methods: A review of technical and surgical 
parameters of IOeRT procedures using LIAC was performed 
from December 2013 to October 2015,  
 
Results: From december 2013 to october 2015, 222 
procedures in 185 patients were performed (200 procedures 
with LIAC, 22 transported to a fixed lineal accelerator). 
Cancer types treated were 64 oligorecurrences / 
oligometastases, 34 breast cancers, 44 rectal cancers, 42 
sarcomas, 6 pancreatic adenocarcinomas, 4 esophageal 
neoplasms and 6 other cancer types. The treated anatomic 
sites included 100 cases in pelvis, 40 in abdomen, 25 in limbs, 
34 in breast and 1 in thorax. Relevant operational data 
included 39 days with more than 2 procedures in the same 
working day (22% of total days). Six different applicator sizes 
were selected (range 4-10) with 4 beveled ends (range 0-45). 
Selected energies ranged from 6 to 12. 
 
Conclusion: LIAC is a versatile technology able to be 
incorporated to expert IORT institutions promoting efficient 
action with operative benefits in terms of availability of 
IOeRT components for cancer patients. 
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Purpose or Objective: There has been a rapid growth in the 
number of immuno- and immunoradiotherapy trials over the 
last few decades. Long term durable responses occur, but 
only in a subset of patients. As yet no accurate method of 
identifying those patients most likely to benefit has been 
identified. The factors behind non-response are unclear but 
may include 1) inherent characteristics of the tumour, 2) 
factors influencing immunogenicity such as tumour burden 
and previous treatments and 3) clinical trial design By 
performing a cross sectional analysis of registered clinical 
trials investigating agents thought to stimulate T-cells we 
aimed to detect trends in these factors. In particular we 
aimed to assess the extent to which trials sought to develop 
and identify novel biomarkers of response to immunotherapy. 
 
Material and Methods: A pubmed literature search was 
conducted to establish a list of known T cell checkpoints, co-
stimulatory receptors, ligands, and the antibodies targeting 
these. These search terms were entered into clinical 
trials.gov on October 11, 2014. Study details were 
downloaded as datasets for review by two independent 
assessors. 
 
Results: We identified a total of 350 trials of 
immunomodulatory antibodies targeting PD-1, CTLA4, PD-L1, 
PD-L2, LAG3, B7-H3, CD137, OX40, CD27 and GITR. A 
longitudinal analysis by trial registration date shows a steady 
increase in the number of trials using immunostimulatory 
antibodies As some cancer types are thought to be more 
immunogenic, we looked at the spread of trials by cancer 
type. Unsurprisingly, melanoma trials represent the largest 
proportion, but there has been a shift towards testing 
immunostimulatory antibodies in cancers that are considered 
less immunogenic with a significant increase in trials in NSLC 
when comparing trials registered between 2000 and 2007 and 
those registered between 2008 and 2014. Only 39% of trials 
measured a dynamic immune endpoint as a specified 
outcome. T and B cell number or function were the most 
common markers analysed. However there was a significant 
increase in the measurement of PD-L1 expression in recent 
years.  
 
Conclusion: This analysis provides comprehensive data on the 
rapid growth of immunotherapy trials and highlights that 
despite the multiplicity and variability of potential dynamic 
biomarkers available, there has been a poor uptake. Whilst 
the future of immunotherapy is not in doubt, biomarkers are 
essential to understand the considerable lack of response and 
help guide further trial efforts. 
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Purpose or Objective: New targeted therapies (nTTs) are 
increasingly used in virtually every type of cancer. On the 
other hand radiation therapy (RT) is frequently applied in the 
curative and palliative setting of cancer treatment, 
confronting clinicians more and more with the problem, 
weather a previously initiated nTT-therapy could be 
continued during RT. The aim of this systematic literature 
analysis was to evaluate the toxicity of concomitant 
application of RT with nTTs in a qualitative descriptive 
manner.  
 
Material and Methods: Clinical studies comprising 
concomitant application of RT with EGFR-, VEGFR-, HDAC-, 
proteasom-, BRAF-, m-Tor- or immune-checkpoint-inhibitors 
were eligible. Using fixed search terms 215 publications were 
identified including more than 6000 patients. Forty-eight 
studies analyzed combinations of nTTs with ZNS-RT including 
1164 patients, 45 with head and neck-RT including 2390 
patients, 59 with thoracic RT including 1647 patients, 33 with 
abdominal RT and 30 with pelvic RT including 492 and 1008 
patients respectively.  
 
Results: In most cases combined application produced no 
additional toxicity or a slight increase of the already known 
toxicity profile. Scarcely, however, combination of RT with 
nTTs resulted in serious side effects. These toxicities 
comprised tracheo-bronchial fistulas or GI-bleeding for 
combinations of thoracic or abdominal/pelvic RT with VEGF-
receptor-inhibitors, recall phenomena in combination of RT 
with tyrosinkinase inhibitors e.g. erlotinib and severe 
mucositis, dermatitis or paraplegia (case report) when 
combining RT with ipilimumab. For the majority of these 
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serious side effects no predictive risk factors could be 
isolated.  
 
Conclusion: The currently available data seems to be not 
adequate to give a general recommendation, on weather RT 
could be combined with nTTs in clinical routine. If 
application is carried out on an individual basis it should be 
done under close clinical surveillance. Multicentric 
observational studies are needed to address this clinical 
relevant problem. 
 
Electronic Poster: Physics track: Basic dosimetry and 
phantom and detector development  
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Purpose or Objective: Over the years, radiochromic film 
became a reference dosimetry system of choice for two-
dimensional dose distribution measurements with acceptable 
accuracy and uncertainty in both clinical and research 
applications. Nonetheless, response of the film might be 
influenced by factors other than irradiation (humidity, 
extreme temperature and/or exposure to UV light) that could 
lead to decreased measurement accuracy. We investigate the 
use of a control film piece, which should compensate for the 
film response changes other than radiation. 
 
Material and Methods: Response of EBT3 film was measured 
in terms of net transmittance calculated using green channel 
from 48-bit RGB image of film pieces scanned with Epson 
Expression 10000 XL flatbed scanner. We established a 
calibration curve for the radiochromic film dosimetry system 
in a dose range up to 20 Gy. Then, we irradiated “control” 
film pieces to several known doses from 0.05, to 1 Gy, as 
well as five film pieces of the same size to “unknown” doses 
of 2, 5, 10, 15 and 20 Gy. Impact of correcting measured 
(“unknown”) doses using “control” film pieces were 
investigated in terms of both gain in the accuracy and at the 
same time loss of uncertainty of such determined dose. 
Depending on a dose range, two approaches of incorporating 
control film piece were investigated. In a signal based 
method, response of the control film piece is subtracted from 
the measuring film piece and the final change in response is 
converted into the dose using calibration curve. In a dose 
based method, both readings of measuring and control film 
pieces are converted to dose using the same calibration curve 
followed by subtracting the control film piece “equivalent” 
dose from the dose obtained with measuring film piece. 
 
Results: Figure 1 summarizes results of our investigation into 
trade-off between gain in accuracy and loss in uncertainty 
when the control film piece is used, and we found that both 
are dependent on dose level measured. For dose values 
above 10 Gy, the increase in accuracy of 3% results in 
uncertainty loss of 5% by using dose corrected approach, 
where the measured film response corresponded to 2% of the 
dose response registered with measuring film piece. At lower 
doses and signals of the order of 5% (measured by control 
film piece) we observed an increase in accuracy of 10% with a 
loss of uncertainty lower than 1% by using the corrected 
signal approach. 
 
 
Conclusion: Use of the control (un-irradiated) film piece for 
dose measurements in reference radiochromic film dosimetry 
is highly recommended. At lower doses, the signal based 
method should be used, while at higher doses the dose 
correction method seems to be more appropriate. However, 
final incorporation of the signal registered by the control film 
piece into dose measurement analysis should be a judgment 
call of the user based on a tradeoff between deemed 
accuracy and acceptable uncertainty for a given dose 
measurement. 
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Purpose or Objective: To estimate and correct the 
systematic bias which results from the intra-chamber dose 
gradients when a Farmer ionization chamber is used for 
reference dosimetry (TRS 398, IAEA 2000) in flattening-filter-
free (FFF) MV photon beams. 
 
Material and Methods: An intra-chamber dose gradient 
correction factor (K_icdg) of the charge reading of a Farmer 
ionization chamber, when used for reference dosimetry (TRS 
398, IAEA 2000) in flattening-filter-free (FFF) MV photon 
beams, is proposed. This is achieved through a user 
intercomparison of the Farmer ionization chamber with a 
small volume (~ 0.1 cm³) ionization chamber, and by 
estimating the inaccuracies of this intercomparison. Further, 
the factor K_icdg is theoretically developed in terms of the 
corrections for both volume averaging effect (P_vol) and 
charged particle fluence perturbation (P_fl). The factor P_vol 
is then estimated as the ratio of the active length (L) of the 
Farmer ionization chamber (L= 24 mm) over the integral, 
computed on L, of a high-resolution FFF transverse dose 
profile (Figure 1). Once K_icdg and P_vol are known, P_fl is 
finally deduced. 
 
Results: The estimated overall standard uncertainties on the 
absorbed dose to water determination in reference 
conditions, for 6 MV and 10 MV FFF beams, were 1.5 % for the 
small volume ionization chamber (30013™, PTW), and 1.4 % 
for the K_icdg-corrected Farmer ionization chamber (30013™, 
PTW). In the latter case, the added uncertainty from the 
measure of K_icdg was balanced by the higher long-term 
stability of the Farmer ionization chamber. From four distinct 
dosimetry sessions on a TrueBeam™ (Varian Inc.) linac, mean 
(sd) values for K_icdg equal to 1.0024 (0.0003) for 6 MV-FFF 
and 1.0056 (0.0003) for 10 MV-FFF, were estimated. 
Similarly, P_vol equal to 1.0030 (0.0001) for 6 MV-FFF, and to 
1.0064 (0.0004) for 10 MV-FFF, respectively, were measured. 
